Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PHD4/HIF Prolyl Hydroxylase 4 Antibody, Alexa Fluor™ 405, Novus Biologicals™

Rabbit Polyclonal Antibody
Supplier: Novus Biologicals NB100295AF405
Description
PHD4/HIF Prolyl Hydroxylase 4 Polyclonal specifically detects PHD4/HIF Prolyl Hydroxylase 4 in Human, Rat, Mouse (Negative) samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
PHD4/HIF Prolyl Hydroxylase 4 | |
Polyclonal | |
Western Blot, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin | |
NP_808808.1 | |
P4HTM | |
The epitope recognized by this antibody maps to a region between residue 450 and the C-terminus (residue 502) of human PHD4/HIF Prolyl Hydroxylase 4 using the numbering given in entry NP_808808.1 (GeneID 54681). | |
Affinity Purified | |
RUO | |
Primary | |
Human. Does not appear to work in Mouse. Rat reactivity reported in scientific literature (PMID: 17003483). | |
Store at 4C in the dark. |
Western Blot, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
Alexa Fluor 405 | |
50mM Sodium Borate with 0.05% Sodium Azide | |
EC 1.14.11.-, EGLN4, HIFPH4, HIF-PH4, HIF-prolyl hydroxylase 4, HPH-4, hypoxia-inducible factor prolyl 4-hydroxylase, Hypoxia-inducible factor prolyl hydroxylase 4, P4H with transmembrane domain, P4H-TMFLJ20262, PH-4, PH4 hypoxia inducible factor prolyl 4 hydroxylase, PHD4, proline 4-hydroxylase, prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum), Prolyl hydroxlase domain-containing 4, transmembrane prolyl 4-hydroxylase | |
Rabbit | |
50 kDa | |
0.1 mL | |
Cancer, Hypoxia, Lipid and Metabolism | |
54681 | |
Human, Rat, Mouse (Negative) | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction